Loading…
News @ a glance
Discount drugs: Pharmaceutical giant Pfizer Inc. is offering discounts on prescription drugs to 43 million uninsured Americans, a move analysts said could be aimed at countering growing pressure for US cost controls. Under the "Pfizer Pfriends" program, uninsured families making less than...
Saved in:
Published in: | Canadian Medical Association journal (CMAJ) 2004-11, Vol.171 (10), p.1162-1163 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1163 |
container_issue | 10 |
container_start_page | 1162 |
container_title | Canadian Medical Association journal (CMAJ) |
container_volume | 171 |
creator | Sibbald, B. |
description | Discount drugs: Pharmaceutical giant Pfizer Inc. is offering discounts on prescription drugs to 43 million uninsured Americans, a move analysts said could be aimed at countering growing pressure for US cost controls. Under the "Pfizer Pfriends" program, uninsured families making less than $45 000 a year will be eligible for average savings of 37%, and uninsured, higher income families could get average savings of 15%. However, analysts said the move may be in the company's best interest. Brandon Carl, a securities analyst for North Carolina-based BB&T Asset Management Inc., which owns 1.8 million shares of Pfizer, said the move appears to be an effort to take "a proactive stance ahead of some of the major changes that could take place in coming years." He pointed to growing pressure for drug price controls and reimportation of lower-priced drugs from Canada and elsewhere. "They want to position themselves so that they're not trying to stand in the way of an obvious problem with the inflation of drug prices," Carl said. The average price of the top 30 brand-name drugs used by senior citizens in the US rose 22% over the past 3 years, according to a study by the advocacy group Families USA. Dr. Steven Morgan, a health economist at the Centre for Health Services and Policy Research at the University of British Columbia, said the Pfizer program fails to get to the heart of the problem, the need for "demand-style systems or government regulations that ensure everyone pays the same price." |
doi_str_mv | 10.1503/cmaj.1041652 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_524943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>742727611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1562-95c61ad7551355d2b5afc7defb044635b95c7f61ddcc91374db1ebd71fa60d413</originalsourceid><addsrcrecordid>eNpVkMtKw0AUhgdRMFZx4wME16bOmWtmISjFGxTd6HqYW2pDLnWmUXx7UxoEz-Yszvf_HD6ELgDPgWN67VpTzwEzEJwcoAxYWRaEEnWIMlwSXFDFxDE6SanG41AiM3T-Er5TfpubfNWYzoVTdFSZJoWzac_Q-8P92-KpWL4-Pi_uloUDLkihuBNgvOQcKOeeWG4qJ32oLGZMUG5HQFYCvHdOAZXMWwjWS6iMwJ4BnaGbfe9msG3wLnTbaBq9ievWxB_dm7X-f-nWH3rVf2lOmGJ0zF9O-dh_DiFtdd0PsRtf1gRzDCCxGqGrPeRin1IM1V8_YL0zpnfG9GSM_gLnCl1N</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205011709</pqid></control><display><type>article</type><title>News @ a glance</title><source>PubMed Central</source><creator>Sibbald, B.</creator><creatorcontrib>Sibbald, B.</creatorcontrib><description>Discount drugs: Pharmaceutical giant Pfizer Inc. is offering discounts on prescription drugs to 43 million uninsured Americans, a move analysts said could be aimed at countering growing pressure for US cost controls. Under the "Pfizer Pfriends" program, uninsured families making less than $45 000 a year will be eligible for average savings of 37%, and uninsured, higher income families could get average savings of 15%. However, analysts said the move may be in the company's best interest. Brandon Carl, a securities analyst for North Carolina-based BB&T Asset Management Inc., which owns 1.8 million shares of Pfizer, said the move appears to be an effort to take "a proactive stance ahead of some of the major changes that could take place in coming years." He pointed to growing pressure for drug price controls and reimportation of lower-priced drugs from Canada and elsewhere. "They want to position themselves so that they're not trying to stand in the way of an obvious problem with the inflation of drug prices," Carl said. The average price of the top 30 brand-name drugs used by senior citizens in the US rose 22% over the past 3 years, according to a study by the advocacy group Families USA. Dr. Steven Morgan, a health economist at the Centre for Health Services and Policy Research at the University of British Columbia, said the Pfizer program fails to get to the heart of the problem, the need for "demand-style systems or government regulations that ensure everyone pays the same price."</description><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>DOI: 10.1503/cmaj.1041652</identifier><identifier>CODEN: CMAJAX</identifier><language>eng</language><publisher>Ottawa: CMA Impact, Inc</publisher><ispartof>Canadian Medical Association journal (CMAJ), 2004-11, Vol.171 (10), p.1162-1163</ispartof><rights>Copyright Canadian Medical Association Nov 9, 2004</rights><rights>2004 Canadian Medical Association or its licensors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC524943/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC524943/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Sibbald, B.</creatorcontrib><title>News @ a glance</title><title>Canadian Medical Association journal (CMAJ)</title><description>Discount drugs: Pharmaceutical giant Pfizer Inc. is offering discounts on prescription drugs to 43 million uninsured Americans, a move analysts said could be aimed at countering growing pressure for US cost controls. Under the "Pfizer Pfriends" program, uninsured families making less than $45 000 a year will be eligible for average savings of 37%, and uninsured, higher income families could get average savings of 15%. However, analysts said the move may be in the company's best interest. Brandon Carl, a securities analyst for North Carolina-based BB&T Asset Management Inc., which owns 1.8 million shares of Pfizer, said the move appears to be an effort to take "a proactive stance ahead of some of the major changes that could take place in coming years." He pointed to growing pressure for drug price controls and reimportation of lower-priced drugs from Canada and elsewhere. "They want to position themselves so that they're not trying to stand in the way of an obvious problem with the inflation of drug prices," Carl said. The average price of the top 30 brand-name drugs used by senior citizens in the US rose 22% over the past 3 years, according to a study by the advocacy group Families USA. Dr. Steven Morgan, a health economist at the Centre for Health Services and Policy Research at the University of British Columbia, said the Pfizer program fails to get to the heart of the problem, the need for "demand-style systems or government regulations that ensure everyone pays the same price."</description><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpVkMtKw0AUhgdRMFZx4wME16bOmWtmISjFGxTd6HqYW2pDLnWmUXx7UxoEz-Yszvf_HD6ELgDPgWN67VpTzwEzEJwcoAxYWRaEEnWIMlwSXFDFxDE6SanG41AiM3T-Er5TfpubfNWYzoVTdFSZJoWzac_Q-8P92-KpWL4-Pi_uloUDLkihuBNgvOQcKOeeWG4qJ32oLGZMUG5HQFYCvHdOAZXMWwjWS6iMwJ4BnaGbfe9msG3wLnTbaBq9ievWxB_dm7X-f-nWH3rVf2lOmGJ0zF9O-dh_DiFtdd0PsRtf1gRzDCCxGqGrPeRin1IM1V8_YL0zpnfG9GSM_gLnCl1N</recordid><startdate>20041109</startdate><enddate>20041109</enddate><creator>Sibbald, B.</creator><general>CMA Impact, Inc</general><general>Canadian Medical Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20041109</creationdate><title>News @ a glance</title><author>Sibbald, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1562-95c61ad7551355d2b5afc7defb044635b95c7f61ddcc91374db1ebd71fa60d413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sibbald, B.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Medical Association journal (CMAJ)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sibbald, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>News @ a glance</atitle><jtitle>Canadian Medical Association journal (CMAJ)</jtitle><date>2004-11-09</date><risdate>2004</risdate><volume>171</volume><issue>10</issue><spage>1162</spage><epage>1163</epage><pages>1162-1163</pages><issn>0820-3946</issn><eissn>1488-2329</eissn><coden>CMAJAX</coden><abstract>Discount drugs: Pharmaceutical giant Pfizer Inc. is offering discounts on prescription drugs to 43 million uninsured Americans, a move analysts said could be aimed at countering growing pressure for US cost controls. Under the "Pfizer Pfriends" program, uninsured families making less than $45 000 a year will be eligible for average savings of 37%, and uninsured, higher income families could get average savings of 15%. However, analysts said the move may be in the company's best interest. Brandon Carl, a securities analyst for North Carolina-based BB&T Asset Management Inc., which owns 1.8 million shares of Pfizer, said the move appears to be an effort to take "a proactive stance ahead of some of the major changes that could take place in coming years." He pointed to growing pressure for drug price controls and reimportation of lower-priced drugs from Canada and elsewhere. "They want to position themselves so that they're not trying to stand in the way of an obvious problem with the inflation of drug prices," Carl said. The average price of the top 30 brand-name drugs used by senior citizens in the US rose 22% over the past 3 years, according to a study by the advocacy group Families USA. Dr. Steven Morgan, a health economist at the Centre for Health Services and Policy Research at the University of British Columbia, said the Pfizer program fails to get to the heart of the problem, the need for "demand-style systems or government regulations that ensure everyone pays the same price."</abstract><cop>Ottawa</cop><pub>CMA Impact, Inc</pub><doi>10.1503/cmaj.1041652</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0820-3946 |
ispartof | Canadian Medical Association journal (CMAJ), 2004-11, Vol.171 (10), p.1162-1163 |
issn | 0820-3946 1488-2329 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_524943 |
source | PubMed Central |
title | News @ a glance |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A24%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=News%20@%20a%20glance&rft.jtitle=Canadian%20Medical%20Association%20journal%20(CMAJ)&rft.au=Sibbald,%20B.&rft.date=2004-11-09&rft.volume=171&rft.issue=10&rft.spage=1162&rft.epage=1163&rft.pages=1162-1163&rft.issn=0820-3946&rft.eissn=1488-2329&rft.coden=CMAJAX&rft_id=info:doi/10.1503/cmaj.1041652&rft_dat=%3Cproquest_pubme%3E742727611%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1562-95c61ad7551355d2b5afc7defb044635b95c7f61ddcc91374db1ebd71fa60d413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=205011709&rft_id=info:pmid/&rfr_iscdi=true |